ABSI - NASDAQ
Absci Corporation
$5.94
-6.5%Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
At a Glance
Live Snapshotabsi
Operating Expenses
Last Annual Value
115.78M
3-Year CAGR
29%
5-Year CAGR
77%
10-Year CAGR
30%
Absci Corporation Competitors Analysis of Operating Expenses
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Absci Corporation NASDAQ:ABSI | 115.78M | 16.3% | 26.7% | N/A | |
 REGENXBIO Inc. NASDAQ:RGNX | 311.34M | -1.0% | 3.8% | 16.3% | |
 Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | 42.87M | 22.3% | 2.1% | 1.5% | |
 Prothena Corporation plc NASDAQ:PRTA | 190.54M | -12.3% | 8.2% | 1.7% | |
 Gossamer Bio, Inc. NASDAQ:GOSS | 210.72M | 4.7% | -0.5% | 119.0% | |
 Verastem, Inc. NASDAQ:VSTM | 195.75M | 28.6% | 25.3% | 18.1% | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 148.45M | -10.6% | 17.2% | N/A | |
 MeiraGTx Holdings plc NASDAQ:MGTX | 182.52M | 6.5% | 10.6% | 24.7% | |
 Erasca, Inc. NASDAQ:ERAS | 128.30M | -2.4% | 0.7% | N/A | |
 Olema Pharmaceuticals, Inc. NASDAQ:OLMA | 178.70M | 19.4% | 20.1% | N/A |
Absci Corporation Fair Value Envelope
Related Guides
Continue your ABSI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.